In adults with cirrhosis and type 2 diabetes, glucagon-like peptide-1 receptor agonist therapy significantly lowered the risk for death and other adverse outcomes, a study found.
2022 JAN 26 By a News Reporter-Staff News Editor at Insurance Daily News Researchers detail new data in Autoimmune Diseases and Conditions- Graves Disease. Funders for this research include Taiwan Ministry of Health and Welfare Clinical Trial Center, China Medical University Hospital, Ministry of Science and Technology. Our news editors obtained a quote.